Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

(2016) A. Patnaik et al.   Cancer Discovery

Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment

(2015) T. VanArsdale et al.   CLINICAL CANCER RESEARCH

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

(2015) Donavan T. Cheng et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation

(2015) A-S Tigan et al.   ONCOGENE

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer

(2015) Ana Bosch et al.   Science Translational Medicine

Targeting CDK4 and CDK6: From Discovery to Therapy

(2015) C. J. Sherr et al.   Cancer Discovery

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

(2014) Lawrence M. Gelbert et al.   INVESTIGATIONAL NEW DRUGS

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies

(2014) Martina McDermott et al.   Frontiers in Oncology

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors

(2012) Jeffry L. Dean et al.   CELL CYCLE

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

(2011) Gottfried E. Konecny et al.   CLINICAL CANCER RESEARCH

ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

(2011) T. W. Miller et al.   Cancer Discovery

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53

(2009) F. Navarro et al.   BLOOD

Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome

(2009) S Umemura et al.   BRITISH JOURNAL OF CANCER

Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

(2008) Qing-Bai She et al.   PLoS One